Stock Earnings

Question 1

Innate Pharma SA'in temel mali tabloları nelerdir?

Accepted Answer

Son mali tabloya (Form-10K) göre, Innate Pharma SA'in toplam varlıkları $111 olup, net loss $-49'dir.

Question 2

IPHYF'ün temel finansal oranları nelerdir?

Accepted Answer

Innate Pharma SA'in cari oranı 1.08, net kâr marjı -408.33, hisse başına satış $0.14'dir.

Question 3

Innate Pharma SA'in geliri segment veya coğrafya bazında nasıl dağılıyor?

Accepted Answer

Innate Pharma SA largest revenue segment is Research and Development of Pharmaceutical Products, at a revenue of 20,121,000 in the most earnings release.For geography, France is the primary market for Innate Pharma SA, at a revenue of 20,121,000.

Question 4

Innate Pharma SA kârlı mı?

Accepted Answer

no, son mali tablolara göre Innate Pharma SA'in net loss $-49'dir.

Question 5

Innate Pharma SA'in herhangi bir yükümlülüğü var mı?

Accepted Answer

yes, Innate Pharma SA'in yükümlülüğü 102'dir.

Question 6

Innate Pharma SA'in tedavüldeki hisse sayısı kaçtır?

Accepted Answer

Innate Pharma SA'in toplam tedavüldeki hisse sayısı 83.81'dir.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	6	12	51	49	12	56
Revenue Growth (YoY)	-75%	-76%	4%	308%	-79%	-18%
Cost of Revenue	3	3	2	3	3	3
Gross Profit	2	9	49	45	9	52
Selling, General & Admin	18	18	16	20	23	17
Research & Development	37	45	49	45	41	37
Operating Expenses	53	61	61	62	56	51
Other Non Operating Income (Expenses)	0	1	1	-1	1	0
Pretax Income	-46	-49	-7	-57	-45	0
Income Tax Expense	0	0	0	0	0	0
Net Income	-46	-49	-7	-58	-52	-63
Net Income Growth	35%	600%	-88%	12%	-17%	215%
Shares Outstanding (Diluted)	86.93	81.05	80.45	79.63	79.54	78.93
Shares Change (YoY)	8%	1%	1%	0%	1%	18%
EPS (Diluted)	-0.54	-0.61	-0.09	-0.72	-0.66	-0.81
EPS Growth	30%	549%	-87%	10%	-19%	161%
Free Cash Flow	-41	-7	-34	-20	-59	-63
Free Cash Flow Per Share	-0.47	-0.08	-0.42	-0.25	-0.74	-0.79
Gross Margin	33.33%	75%	96.07%	91.83%	75%	92.85%
Operating Margin	-833.33%	-425%	-23.52%	-32.65%	-391.66%	1.78%
Profit Margin	-766.66%	-408.33%	-13.72%	-118.36%	-433.33%	-112.5%
Free Cash Flow Margin	-683.33%	-58.33%	-66.66%	-40.81%	-491.66%	-112.5%
EBITDA	-49	-50	-7	29	-43	57
EBITDA Margin	-816.66%	-416.66%	-13.72%	59.18%	-358.33%	101.78%
D&A For EBITDA	1	1	5	45	4	56
EBIT	-50	-51	-12	-16	-47	1
EBIT Margin	-833.33%	-425%	-23.52%	-32.65%	-391.66%	1.78%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Innate Pharma SA (IPHYF) Price

IPHYF Stock Price Chart

IPHYF Income

Follow-Up Questions